Abiopharma

🔍 Sawyer Jason David (Director)

Company: LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 25,000 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 25,000 shares of Options to Purchase Common Stock at $3.59 per share (Derivative)
  Date: 2026-04-15 | Code: D | Expires: 2030-08-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.
• F2: The canceled Options provided for vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested.